Navigation Links
Dana-Farber receive $5.6 million grant to develop rapid countermeasures to infectious agents
Date:1/18/2011

BOSTON--Researchers at Dana-Farber Cancer Institute have received a $5.6 million grant from the Defense Advanced Research Projects Agency (DARPA) and the Army Research Office (ARO) to develop transient immunity against known, unknown, naturally occurring, or engineered disease-causing pathogens. The ultimate goal is to develop a viable countermeasure to an unknown pathogen within seven days of receiving it in a laboratory.

Wayne A. Marasco, MD, PhD, of the Department of Cancer Immunology and AIDS at Dana-Farber and an associate professor of Medicine at Harvard Medical School, is the project's principal investigator.

Since the mid 1990's, DARPA's Defense Sciences Office has pioneered advances across the full spectrum of bio-warfare defense needs, including the development of advanced diagnostics and medical therapies that are active against an entire range of infectious agents.

"This grant will support revolutionary advances in rapid response to naturally evolving and engineered pathogens," says Marasco. "DARPA has issued a challenge to develop a treatment to unknown threats in just seven days, and we are excited about the opportunity to meet this challenge."

Disease-causing pathogens can be spread through natural and intentional means. Factors responsible for the increase in newly emerging and re-emerging pathogens include increased animal-human interface, increased population densities and international travel, climate change as it affects migration of animals such as birds, some of which could be disease carriers and the narrowing of genetic diversity among food animal stocks.

In addition, the proliferation of genetic engineering technologies that can be easily redirected from beneficent to offensive purposes, and the covert biological sabotage of food animals are all great biodefense concerns.

"In the past, medical responses to large-scale disease outbreaks have been very slow," said Marasco. "Often it has taken many months to years to research and create medicines or vaccines, time barriers that often result in loss of life. This program gives us an opportunity to very rapidly provide ways to prevent infection and extend survival until long-term solutions are available."

Marasco will direct an international team of leading scientists and businesses engaged in the study of pathogen detection, screening, and therapeutic formulation and manufacturing. The team will pursue two parallel paths toward the program goals: First, to rapidly select broadly neutralizing phage antibodies for direct use as therapeutics for microbial infection; and Second, to investigate selective anti-idiotypic stimulation of B-cell precursors leading to secretion of antibodies with broad-spectrum, natural, anti-microbial activity.


'/>"/>

Contact: Bill Schaller
william_schaller@dfci.harvard.edu
617-632-5357
Dana-Farber Cancer Institute
Source:Eurekalert

Related biology news :

1. Dana-Farber oncologists present at ASCO GU -- predict prostate cancer survival using Source MDx test
2. Dana-Farber and sanofi-aventis establish cancer research alliance
3. Wistar Institute researcher receives New Innovator award from NIH
4. L-1 Identity Solutions Receives $5.9 Million Drivers License Contract Expansion from the State of Mississippi
5. Kount Receives Patent for Device Fingerprinting
6. American College of Medical Genetics receives $13.5M NIH contract
7. Carnegie Mellon to receive $900,000 from EPA for brownfields research
8. Penn State receives new NASA astrobiology grant
9. Salk scientist Fred H. Gage to receive the Keio Medical Science Prize
10. Global Viral Forecasting Initiative receives $11M to implement pandemic early warning system
11. Vidaza receives positve opinion from European CHMP
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/31/2017)... 31, 2017  Spero Therapeutics, LLC, a biopharmaceutical ... treatment of bacterial infections, today announced it has ... from Pro Bono Bio Ltd (PBB) to bolster ... resistant forms of Gram-negative bacteria.   The assets acquired ... a PBB group company. "The acquisition ...
(Date:1/24/2017)... , Jan. 24, 2017 Biopharm Reports ... the laboratory use of nuclear magnetic resonance spectroscopy ... end-users and profiled current practices, developments, trends and ... well as growth and opportunities. These areas include ... NMR instruments, needs and innovation requirements, hyphenated NMR ...
(Date:1/19/2017)... 2017 Sensory Inc ., a ... for consumer electronics, and i nnerCore ... cybersecurity solutions, today announced a global partnership that ... worldwide to bolster security of data sensitive mobile ... authentication platforms they offer, innerCore now offers its ...
Breaking Biology News(10 mins):
(Date:2/22/2017)... (PRWEB) , ... February 22, 2017 , ... ... that is has acquired Kendall Research Systems, LLC (KRS) clinical development ... that develops neural interface technology for research and clinical applications. The terms of ...
(Date:2/22/2017)... ... February 22, 2017 , ... ... leading medical education provider of women’s health, primary care, and specialty education, ... for Continuing Medical Education (ACCME). ACCME’s Accreditation with Commendation is a six-year ...
(Date:2/22/2017)... Dublin - Research and Markets has ... Market-By Type, By Application, By End User, By Region, By Country: ... ... Market is forecasted to grow at a CAGR of 11.33% during ... crop protection market is driven by the surging demand for less ...
(Date:2/22/2017)... ... February 22, 2017 , ... ... addition of Tom Perkins as European director. Operating from Pennside’s Zurich headquarters, Pennside ... , Perkins joins Pennside after more than a decade with leading market ...
Breaking Biology Technology: